Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06388083 · ClinicalTrials.gov registry record · Phase 2
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
A Phase 2 study of Stargardt Disease 1 and STGD1, sponsored by Belite Bio.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 18
- Study locations
NCT06388083 is a Phase 2 study of Stargardt Disease 1 and STGD1 that is active but no longer recruiting, run by Belite Bio. The registered enrollment target is 60 participants. The trial reports 18 study locations across 10 states.
The verdict
NCT06388083, a Phase 2 study of Stargardt Disease 1 and STGD1, is active but no longer recruiting, sponsored by Belite Bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 18
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tinlarebant
Study Locations (18)
Other
- Belite Study Site - Kobe
- Belite Study Site - Kyoto
- Belite Study Site - Tokyo
- UK01 Belite Study Site - London
Texas
- Belite Study Site - US13 - Austin
- Belite Study Site - US03 - Dallas
- Belite Study Site - US12 - The Woodlands
California
- Belite Study Site - US05 - La Jolla
- Belite Study Site - US09 - San Francisco
Minnesota
- Belite Study Site - US11 - Edina
- Belite Study Site - US04 - Rochester
New York
- Belite Study Site - US14 - New York
- Belite Study Site - US10 - Westbury
Arizona
- Belite Study Site - US08 - Phoenix
Florida
- Belite Study Site - US06 - Miami
Massachusetts
- Belite Study Site - US01 - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-07-31 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06388083
The ClinicalTrials.gov registry entry for NCT06388083 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Belite Bio, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stargardt Disease 1 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06388083 reports 18 study locations spanning 10 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06388083 about?
NCT06388083 is a clinical study titled "A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease". The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease
What is the current status of trial NCT06388083?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-07-31. Estimated completion is 2028-02.
What conditions does trial NCT06388083 study?
This clinical trial studies the following conditions: Stargardt Disease 1, STGD1.
What interventions are being tested in trial NCT06388083?
The interventions under investigation include: Placebo (DRUG), Tinlarebant (DRUG).
Who is sponsoring clinical trial NCT06388083?
This trial is sponsored by Belite Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06388083 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt Disease 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.